Delamanid-based Regimen (longer course)
Treatment for Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Typical Dosage: Delamanid 100mg twice daily for 6 months, combined with other second-line drugs for full duration
Effectiveness
78%
Safety Score
60%
Clinical Trials
30
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Delamanid 100mg twice daily for 6 months, combined with other second-line drugs for full duration
Time to Effect
2-3 months for culture conversion
Treatment Duration
18-24 months
Evidence Quality
HIGHConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$14,000
Monitoring:$4,000
Side Effect Mgmt:$2,500
Total Annual:$20,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$110,000/QALY
QALYs Gained
0.65
Outcome-Based Costs
Cost per Responder
$26,282
Cost per Remission
$28,082
Comparison vs Injectable-containing MDR-TB regimen
Cost Difference
+$1,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Delamanid-based Regimen (longer course) Outcomes
for Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+78%
Remission Rate
+73%
Common Side Effects
QT prolongation (Delamanid)
+15%
Nausea/Vomiting
+10%
Headache
+8%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov